Department of Gynecology and Obstetrics, North China University of Science and Technology Affiliated Hospital, No. 73, Jianshe South Road, Tangshan, 063000, China.
Department of Group Office, Tangshan People's Hospital, Tangshan, China.
Ir J Med Sci. 2022 Feb;191(1):147-154. doi: 10.1007/s11845-021-02516-3. Epub 2021 Feb 10.
This study aimed to investigate the correlation of sirtuin2 (SIRT2) with clinical characteristics, prognosis in endometrial cancer (EC) patients, and its effect on chemosensitivity in EC cell lines.
A total of 137 EC patients who underwent surgical resection were retrospectively enrolled. SIRT2 expression in tumor tissues (n = 137) and adjacent tissues (n = 61) was detected by immunohistochemistry (IHC) staining and evaluated by a semiquantitative scoring method. EC patients' clinical characteristics and survival data were collected. Besides, SIRT2 was modulated by plasmid transfection in EC cells, then their chemosensitivity to cisplatin and paclitaxel was evaluated.
SIRT2 was increased in tumor tissues compared with adjacent tissues (reflected by both IHC score and high-expression ratio, both P < 0.001). Meanwhile, tumor SIRT2 was positively correlated with lymph node metastasis (P = 0.037) and the International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.044), but not other clinical characteristics. Moreover, tumor SIRT2 high expression was correlated with worse overall survival (OS) (P = 0.023), while it could not independently predict OS (P = 0.090, hazard ratio = 2.782). Besides, both mRNA and protein levels of SIRT2 were increased in Ishikawa (P = 0.035) and KLE (P < 0.001) cells compared with human endometrial epithelial cells. SIRT2 overexpression decreased chemosensitivity to cisplatin and paclitaxel in Ishikawa cells, while SIRT2 knockdown increased chemosensitivity to cisplatin and paclitaxel in KLE cells (all P < 0.05).
SIRT2 correlates with lymph node metastasis, increased FIGO stage, worse OS, and reduced chemosensitivity to cisplatin and paclitaxel in EC.
本研究旨在探讨 SIRT2 与子宫内膜癌(EC)患者临床特征、预后的相关性,及其对 EC 细胞系化疗敏感性的影响。
回顾性纳入 137 例接受手术切除的 EC 患者。采用免疫组织化学(IHC)染色检测肿瘤组织(n=137)和相邻组织(n=61)中 SIRT2 的表达,并采用半定量评分法进行评估。收集 EC 患者的临床特征和生存数据。此外,通过质粒转染调节 EC 细胞中的 SIRT2,然后评估其对顺铂和紫杉醇的化疗敏感性。
肿瘤组织中 SIRT2 的表达高于相邻组织(通过 IHC 评分和高表达比例均反映,均 P<0.001)。同时,肿瘤 SIRT2 与淋巴结转移(P=0.037)和国际妇产科联合会(FIGO)分期(P=0.044)呈正相关,但与其他临床特征无关。此外,肿瘤 SIRT2 高表达与总生存(OS)较差相关(P=0.023),但不能独立预测 OS(P=0.090,风险比=2.782)。此外,与正常子宫内膜上皮细胞相比,Ishikawa(P=0.035)和 KLE(P<0.001)细胞中 SIRT2 的 mRNA 和蛋白水平均升高。SIRT2 过表达降低了 Ishikawa 细胞对顺铂和紫杉醇的化疗敏感性,而 SIRT2 敲低增加了 KLE 细胞对顺铂和紫杉醇的化疗敏感性(均 P<0.05)。
SIRT2 与 EC 的淋巴结转移、FIGO 分期升高、OS 较差以及对顺铂和紫杉醇的化疗敏感性降低相关。